

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Lenvima

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:	Filone.	
Group Number:	NPI:	State Lic ID:	
Address:	Address:	State Lie 15.	
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name	e (if applicable):	
Drug Name and Strength:			
Directions / SIG:			
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.			
Q1. Please provide ICD code(s) for diagnosis.			
Q2. What diagnosis is Lenvima being prescribed for?			
☐ Differentiated Thyroid Cancer (DTC)			
Renal Cell Cancer, Advanced (RCC)			
☐ other			
Q3. If you selected "no" in question 2, please provide doc recommendation per NCCN compendia or guidelines.	umentation that use is	consistent with a category 2A or higher	
Q4. Is prescribing physician a hematology or oncology sp	ecialist?		
☐ Yes ☐ No			
Q5. If the diagnosis is differentiated thyroid cancer, is it lo refractory DTC?	cally recurrent or meta	static, progressive, radioactive iodine-	
☐ Yes ☐ No			
Q6. If the diagnosis is renal cell cancer, will Lenvima be u	sed in combination wit	h everolimus?	



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Lenvima

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

blank or illegible may delay the review process.		
		Prescriber Name:
Patient Name:		Supervising Physician:
Yes	□No	
Q7. If the diagnosis i	is renal cell cancer, has the patient re	ceived one prior anti-angiogenic therapy?
☐ Yes	□ No	
Q8. Additional Comr	nents	
F	Prescriber Signature	Date
		ve, I certify that applying the standard review timeframe may enrollee's ability to regain maximum function
		essity denial. Requesting providers may speak to the SWHP medical nity to help impact the decision on a request before coverage has been
This telecopy transmission cont	ains confidential information belonging to the sender	that is legally privileged. This information is intended only for the use of the individual or

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document